Primary PCL: study identifies independent predictors of survival

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • For patients with primary plasma cell leukemia (pPCL), outcomes may be optimized through upfront autologous stem cell transplantation (ASCT) and novel approaches including proteasome inhibitors and immunomodulators.

Why this matters

  • Data are limited regarding clinical characteristics and outcomes in patients with PCL.

Study design

  • Multicenter study to investigate clinical characteristics, outcomes, and prognostic factors in 117 patients with pPCL.
  • Median age: 61 years (range, 27-85 years).
  • Funding: None disclosed.

Key results

  • 50 months (95% CI, 33-76 months) median follow-up.
  • 78% overall response rate.
  • 21% complete response, 22% very good partial response, 36% partial response, and 22% no response.
  • 35 months (95% CI, 24.3-46 months) median OS in patients who received upfront ASCT vs 13 months (95% CI, 6.3-35.8 months) in patients who did not (Log-rank P<.001>
  • 3 independent predictors of inferior survival were identified in multivariate analyses: age ≥60 years, platelet count ≤100×109/L, and peripheral blood plasma cell count ≥20×109/L.
  • 46 months (95% CI, 33-not reached) median OS in patients with no independent predictors, 27 months (95% CI, 14-41 months) with 1 independent predictor, and 12 months with 2-3 independent predictors (95% CI, 6-20 months).

Limitations

  • Retrospective data.